Shenzhen Salubris Pharmaceuticals

Shenzhen Salubris Pharmaceuticals

Founded in 1998 by Ye Chenghai, Shenzhen Salubris Pharmaceuticals went public on the Shenzhen Stock Exchange in 2009 under the leadership of his son, Kevin Ye, who now serves as CEO and Chairman. The firm has evolved from a domestic pharmaceutical manufacturer into an integrated enterprise with a defined research pipeline targeting cardiovascular, kidney, and metabolic diseases, while the family's First Priority Group vehicle holds a portfolio of industrial and logistics parks concentrated in the Greater Bay Area and Yangtze River Delta. The firm's pharmaceutical strategy centers on innovative drug R&D, with the company's website positioning it as a leader in cardiovascular and chronic kidney disease treatments. Its pipeline has produced notable approvals: the biologic drug Xin Fu Tai Plus became China's first domestically approved teriparatide biosimilar, and an siRNA candidate, SAL0195, entered clinical trials. Beyond drug development, the family's First Priority Group owns a portfolio of industrial and logistics parks in Guangdong and Zhejiang provinces, including the Dongguan Changping Logistics Park and a three-phase Hangzhou logistics campus. The Carlyle Group disclosed a 5% stake in the listed entity through its CAP V Mauritius fund, confirming institutional co-investor alignment. Total deployment figures are undisclosed. The family maintains distinct operational vehicles: the public pharmaceutical company, the privately held First Priority Group managing real assets, and the Ye Chenghai Charity Foundation. Ye Chenghai holds a Vice Chairman seat on the Renmin University Board of Directors, where the family also established a dedicated fund, while the company chairs the Shenzhen Biomedical Industry Alliance. The firm operates from its Shenzhen headquarters with additional R&D facilities inside the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. The family's architecture separates public-market pharmaceutical operations from private real-asset holdings through First Priority Group, a structure that allows the listed entity to focus on drug development while family-controlled vehicles amass industrial property in China's most productive logistics corridors. This separation, combined with the retained role of three Ye family members across the board and executive leadership, makes it a corporate investor with concentrated family control rather than a distributed institutional owner.